UBS lowered the firm’s price target on Afya (AFYA) to $18 from $19 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFYA:
- Afya downgraded to Neutral from Overweight at JPMorgan
- Afya Limited Announces Upcoming Board of Directors Change
- Afya price target lowered to $22 from $25.50 at BofA
- Afya Limited’s Earnings Call Highlights Robust Growth
- Afya’s Balanced Outlook: Revenue Growth Amidst Potential Challenges Justifies Hold Rating